Top 200 Pharmaceuticals by Retail Sales in 2021

Compiled and Produced by M. Haziq Qureshi from the Njarðarson Group (The University of Arizona)

1 **Comirnaty** (COVID-19 Vaccine, mRNA) $36,781 Billion Vaccine	2 **Humira** (Adalimumab) $21,874 Billion Immunology	3 **Spikevax** (COVID-19 Vaccine, mRNA) $17,675 Billion Vaccine	4 **Keytruda** (Pembrolizumab) $17,186 Billion Oncology	5 **Eliquis** (Apixaban) $16,732 Billion Cardiovascular Diseases	6 **Revlimid** (Lenalidomide) $12,898 Billion Oncology	7 **Imbruvica** (Ibrutinib) $9,777 Billion Oncology	8 **Stelara** (Ustekinumab) $9,54 Billion Immunology	9 **Eylea** (Aflibercept) $9,005 Billion Ophthalmology	10 **Biktarvy** (Bictegravir/Emtricitabine/Tenofovir Alafenamide) $8,624 Billion Infectious Diseases	11 **Opdivo** (Nivolumab) $8,431 Billion Oncology	12 **Xarelto** (Rivaroxaban) $7,651 Billion Cardiovascular Diseases	13 **REGEN-COV** (Casirivimab/Imdevimab) $7,582 Billion Infectious Diseases	14 **Trulicity** (Dulaglutide) $6,757 Billion Diabetes	15 **Enbrel** (Etanercept) $6,211 Billion Immunology	16 **Darzalex** (Daratumumab) $6,023 Billion Oncology	17 **Ozempic** (Semaglutide) $5,875 Billion Diabetes	18 **Jardiance** (Empagliflozin) $5,829 Billion Diabetes	19 **Prolia** (Denosumab) $5,798 Billion Musculoskeletal	20 **Dupixent** (Dupilumab) $5,779 Billion Dermatology
21 **Trikafta** (Elexacaftor/Tezacaftor/Ivacaftor) $5,697 Billion Genetic Disorders	22 **Gardasil** (HPV Quadrivalent Vaccine) $5,673 Billion Vaccine	23 **Xtandi** (Enzalutamide) $5,636 Billion Oncology	24 **Veklury** (Remdesivir) $5,565 Billion Infectious Diseases	25 **Ocrevus** (Ocrelizumab) $5,44 Billion Neurology	26 **Ibrance** (Palbociclib) $5,437 Billion Oncology	27 **Prevnar 13** (Pneumococcal 7-Valent Conjugate) $5,272 Billion Vaccine	28 **Tagrisso** (Osimertinib) $5,015 Billion Oncology	29 **Insulin Glargine** (Insulin Glargine) $4,92 Billion Diabetes	30 **Cosentyx** (Secukinumab) $4,718 Billion Immunology	31 **Remicade** (Infliximab) $4,494 Billion Immunology	32 **Entyvio** (Vedolizumab) $4,267 Billion Gastrointestinal Disorders	33 **Perjeta** (Pertuzumab) $4,256 Billion Oncology	34 **Invega Sustenna** (Paliperidone Palmitate) $4,022 Billion Neurology	35 **Vaxzevria** (ChAdOx1-SARS-COV-2) $3,917 Billion Vaccine	36 **Actemra** (Tocilizumab) $3,833 Billion Immunology	37 **Influenza Vaccines** (Influenza Vaccine) $3,812 Billion Vaccine	38 **Lucentis** (Ranibizumab) $3,616 Billion Ophthalmology	39 **Victoza** (Liraglutide) $3,575 Billion Diabetes	40 **Tecentriq** (Atezolizumab) $3,568 Billion Oncology
41 **Entresto** (Sacubitril/Valsartan) $3,548 Billion Cardiovascular Diseases	42 **Xolair** (Omalizumab) $3,518 Billion Immunology	43 **Orencia** (Abatacept) $3,497 Billion Immunology	44 **Herceptin** (Trastuzumab) $3,471 Billion Oncology	45 **Simponi** (Golimumab) $3,467 Billion Immunology	46 **Lynparza** (Olaparib) $3,337 Billion Oncology	47 **Pomalyst** (Pomalidomide) $3,332 Billion Oncology	48 **Januvia** (Sitagliptin) $3,324 Billion Diabetes	49 **Avastin** (Bevacizumab) $3,289 Billion Oncology	50 **Farxiga** (Dapagliflozin) $3,274 Billion Diabetes	51 **Hemlibra** (Emicizumab) $3,252 Billion Hematology	52 **Immunoglobulin** (Immunoglobulin) $3,082 Billion Immunology	53 **Skyrizi** (Risankizumab) $2,939 Billion Immunology	54 **Genvoya** (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) $2,879 Billion Infectious Diseases	55 **Rituxan** (Rituximab) $2,855 Billion Neurology	56 **Gilenya** (Fingolimod) $2,787 Billion Neurology	57 **Ofev** (Nintedanib) $2,743 Billion Respiratory Disorders	58 **Symbicort** (Budesonide/Formoterol) $2,728 Billion Respiratory Disorders	59 **Insulin Aspart** (Insulin Aspart) $2,696 Billion Diabetes	60 **Vyvanse** (Lisdexamfetamine) $2,652 Billion Neurology
61 **Triumeq** (Abacavir/Dolutegravir/Lamivudine) $2,547 Billion Infectious Diseases	62 **Xeljanz** (Tofacitinib Citrate) $2,455 Billion Immunology	63 **Insulin Lispro** (Insulin Lispro) $2,453 Billion Diabetes	64 **Imfinzi** (Durvalumab) $2,412 Billion Oncology	65 **Polio/Pertussis/Hib** (DTaP - IPV - Hib Vaccine) $2,377 Billion Vaccine	66 **Fumarate** (Diroximel Fumarate) $2,362 Billion Neurology	67 **Shingrix** (Zoster Vaccine) $2,329 Billion Vaccine	68 **Zytiga** (Abiraterone Acetate) $2,297 Billion Oncology	69 **Otezla** (Apremilast) $2,249 Billion Dermatology	70 **COVID-19 Antibodies** (Bamlanivimab) $2,239 Billion Infectious Diseases	71 **Advate** (Antihemophilic Factor (Recombinant)) $2,229 Billion Hematology	72 **Taltz** (Ixekizumab) $2,213 Billion Immunology	73 **Aubagio** (Teriflunomide) $2,152 Billion Neurology	74 **Lenvima** (Lenvatinib) $2,149 Billion Oncology	75 **MMR Vaccines** (Measles, Mumps, Rubella & Varicella Vaccines) $2,135 Billion Vaccine	76 **Kadcyla** (Trastuzumab Emtansine) $2,133 Billion Oncology	77 **Tremfya** (Guselkumab) $2,127 Billion Immunology	78 **Cimzia** (Certolizumab pegol) $2,12 Billion Infectious Diseases	79 **Sprycel** (Dasatinib) $2,117 Billion Oncology	80 **Prezcobix** (Darunavir/Cobicistat) $2,083 Billion Infectious Diseases
81 **Tysabri** (Natalizumab) $2,063 Billion Neurology	82 **Alimta** (Pemetrexed) $2,061 Billion Oncology	83 **Tasigna** (Nilotinib) $2,06 Billion Oncology	84 **Neulasta** (Pegfilgrastim) $2,027 Billion Hematology	85 **Yervoy** (Ipilimumab) $2,026 Billion Oncology	86 **Promacta** (Eltrombopag) $2,016 Billion Oncology	87 **Vyndamax** (Tafamidis) $2,015 Billion Rare Disorders	88 **Janumet** (Sitagliptin/Metformin) $1,964 Billion Diabetes	89 **Relvar** (Fluticasone Furoate) $1,92 Billion Respiratory Disorders	90 **Spinraza** (Nusinersen) $1,905 Billion Genetic Disorders	91 **Soliris** (Eculizumab) $1,874 Billion Hematology	92 **Tivicay** (Dolutegravir) $1,869 Billion Infectious Diseases	93 **Vimpat** (Lacosamide) $1,851 Billion Neurology	94 **Advair** (Salmeterol) $1,836 Billion Respiratory Disorders	95 **Venclexta** (Venetoclax) $1,82 Billion Oncology	96 **Opsumit** (Macitentan) $1,819 Billion Cardiovascular Diseases	97 **Abilify Maintena** (Aripiprazole) $1,769 Billion Neurology	98 **Latuda** (Lurasidone) $1,764 Billion Neurology	99 **Aranesp** (Darbepoetin Alfa) $1,756 Billion Hematology	100 **Vraylar** (Cariprazine) $1,728 Billion Neurology
101 **Mavyret** (Glecaprevir/Pibrentasvir) $1,71 Billion Infectious Diseases	102 **Jentadueto** (Linagliptin/Metformin) $1,709 Billion Diabetes	103 **Spiriva** (Tiotropium) $1,704 Billion Respiratory Disorders	104 **Descovy** (Emtricitabine/Tenofovir Alafenamide) $1,7 Billion Infectious Diseases	105 **Tafinlar** (Dabrafenib/Trametinib) $1,693 Billion Oncology	106 **Rinvoq** (Upadacitinib) $1,651 Billion Immunology	107 **Lupron** (Leuprolide) $1,648 Billion Oncology	108 **Trelegy Ellipta** (Fluticasone Furoate/Vilanterol Trifenatate/Umeclidinium) $1,647 Billion Respiratory Disorders	109 **Xifaxan** (Rifaximin) $1,645 Billion Infectious Diseases	110 **Lovenox** (Enoxaparin) $1,636 Billion Hematology	111 **Jynarque** (Tolvaptan) $1,624 Billion Cardiovascular Diseases	112 **Jakavi** (Ruxolitinib) $1,595 Billion Oncology	113 **Odefsey** (Emtricitabine/Rilpivirine/Tenofovir Alafenamide) $1,568 Billion Infectious Diseases	114 **Interferon** (Interferon Beta-1a) $1,566 Billion Neurology	115 **Prograf** (Tacrolimus) $1,566 Billion Immunology	116 **Nucala** (Mepolizumab) $1,545 Billion Respiratory Disorders	117 **Lixiana** (Edoxaban) $1,545 Billion Hematology	118 **RotaTeq** (Rotavirus Vaccine) $1,539 Billion Vaccine	119 **Juvederm** (Hyaluronic Acid) $1,535 Billion Dermatology	120 **Bridion** (Sugammadex) $1,532 Billion Neurology
121 **Insulin Degludec** (Insulin Degludec) $1,483 Billion Diabetes	122 **Brilinta** (Ticagrelor) $1,462 Billion Cardiovascular Diseases	123 **Epclusa** (Sofosbuvir/Velpatasvir) $1,462 Billion Infectious Diseases	124 **Alecensa** (Alectinib) $1,459 Billion Oncology	125 **Rexulti** (Brexpiprazole) $1,457 Billion Neurology	126 **Pradaxa** (Dabigatran Etexilate) $1,451 Billion Hematology	127 **NovoMix** (Biphasic Insulin Aspart) $1,447 Billion Diabetes	128 **Infanrix** (Diphtheria, Tetanus Acellular, & Pertussis) $1,44 Billion Vaccine	129 **Abraxane** (Paclitaxel Protein Bound) $1,423 Billion Oncology	130 **Myrbetriq** (Mirabegron) $1,42 Billion Nephrology	131 **Sandostatin** (Octreotide) $1,413 Billion Oncology	132 **Activase/TNKase** (Alteplase/Tenecteplase) $1,412 Billion Cardiovascular Diseases	133 **Human Insulins** (Human Insulin) $1,38 Billion Diabetes	134 **Afinitor** (Everolimus) $1,369 Billion Oncology	135 **Zolgensma** (onasemnogene abeparvovec-xioi) $1,351 Billion Neurology	136 **Verzenio** (Abemaciclib) $1,35 Billion Oncology	137 **Nexium** (Esomeprazole) $1,326 Billion Gastrointestinal Disorders	138 **Somatuline** (Lanreotide) $1,324 Billion Oncology	139 **Xevudy** (Sotrovimab) $1,296 Billion Infectious Diseases	140 **Erleada** (Apalutamide) $1,291 Billion Oncology
141 **Restasis** (Cyclosporine) $1,29 Billion Immunology	142 **Mirena** (Levonorgestrel) $1,288 Billion Urology	143 **Xyrem** (Sodium Oxybate) $1,266 Billion Sleep	144 **Fasenra** (Benralizumab) $1,258 Billion Respiratory Disorders	145 **Bexsero** (Meningococcal Vaccine) $1,248 Billion Vaccine	146 **Calquence** (Acalabrutinib) $1,238 Billion Oncology	147 **Uptravi** (Selexipag) $1,237 Billion Cardiovascular Diseases	148 **Insulin Isophane** (Insulin Isophane) $1,223 Billion Diabetes	149 **Trintellix** (Vortioxetine) $1,207 Billion Neurology	150 **Creon** (Pancrelipase) $1,191 Billion Rare Disorders	151 **Benlysta** (Belimumab) $1,183 Billion Rare Disorders	152 **Kyprolis** (Carfilzomib) $1,177 Billion Oncology	153 **Myasi** (Bevacizumab-awwb) $1,166 Billion Oncology	154 **Repatha** (Evolocumab) $1,165 Billion Cardiovascular Diseases	155 **Crestor** (Rosuvastatin) $1,158 Billion Cardiovascular Diseases	156 **Esbriet** (Pirfenidone) $1,154 Billion Immunology	157 **Olumiant** (Baricitinib) $1,115 Billion Immunology	158 **Myozyme** (Alglucosidase Alfa) $1,104 Billion Rare Disorders	159 **NovoSeven** (Coagulation Factor VIIa) $1,101 Billion Hematology	160 **Linzess** (Linaclotide) $1,096 Billion Gastrointestinal Disorders
161 **Galvus Group** (Vildagliptin) $1,092 Billion Diabetes	162 **Nplate** (Romiplostim) $1,089 Billion Immunology	163 **Vectibix** (Panitumumab) $1,082 Billion Oncology	164 **Ingrezza** (Valbenazine) $1,082 Billion Neurology	165 **Keppra** (Levetiracetam) $1,068 Billion Neurology	166 **Dovato** (Dolutegravir/Lamivudine) $1,065 Billion Infectious Diseases	167 **Adempas** (Riociguat) $1,065 Billion Cardiovascular Diseases	168 **Ilaris** (Canakinumab) $1,059 Billion Rare Disorders	169 **Cyramza** (Ramucirumab) $1,033 Billion Oncology	170 **Gleevec** (Imatinib) $1,024 Billion Oncology	171 **Plavix** (Clopidogrel) $1,023 Billion Cardiovascular Diseases	172 **Nexgard** (Afoxolaner) $1,009 Billion Infectious Diseases	173 **Copaxone** (Glatiramer acetate) $1,005 Billion Neurology	174 **Inlyta** (Axitinib) $1,002 Billion Oncology	175 **Epogen** (Epoetin Alfa) $1 Billion Hematology	176 **Edurant** (Rilpivirine) $994 Million Infectious Diseases	177 **Ventolin** (Albuterol) $972 Million Respiratory Disorders	178 **Pulmicort** (Budesonide) $970 Million Respiratory Disorders	179 **Insulin Glulisine** (Insulin Glulisine) $966 Million Diabetes	180 **Molnupiravir** (Molnupiravir) $952 Million Infectious Diseases
181 **Seloken** (Metoprolol) $951 Million Cardiovascular Diseases	182 **Zoladex** (Goserelin) $948 Million Oncology	183 **Kisqali** (Ribociclib) $937 Million Oncology	184 **Fabrazyme** (Agalsidase Beta) $929 Million Rare Disorders	185 **Velcade** (Bortezomib) $925 Million Oncology	186 **Vemlidy** (Tenofovir Disoproxil) $925 Million Infectious Diseases	187 **Vasostrict** (Vasopressin) $902 Million Nephrology	188 **Exforge Group** (Amlodipine/Valsartan) $901 Million Cardiovascular Diseases	189 **Pneumovax 23** (Pneumococcal Vaccine Polyvalent) $893 Million Vaccine	190 **Insulin Detemir** (Insulin Detemir) $865 Million Diabetes	191 **Adalat** (Nifedipine) $840 Million Cardiovascular Diseases	192 **Takhzyro** (Lanadelumab-flyo) $838 Million Genetic Disorders	193 **Takecab** (Vonoprazan) $837 Million Gastrointestinal Disorders	194 **YAZ** (Drospirenone/Ethinyl Estradiol) $815 Million Urology	195 **Austedo** (Deutetrabenazine) $802 Million Neurology	196 **Forteo** (Teriparatide) $802 Million Musculoskeletal	197 **Evenity** (Romosozumab-aqqg) $776 Million Musculoskeletal	198 **Cialis** (Tadalafil) $774 Million Urology	199 **Diovan Group** (Hydrochlorothiazide/Valsartan) $773 Million Cardiovascular Diseases	200 **Orkambi** (Lumacaftor/Ivacaftor) $772 Million Respiratory Disorders

Key	Oncology	CNS & Anesthesia	Diabetes	Cardiovascular Diseases	Infectious Diseases	Respiratory Disorders	Immunology	Miscellanious